Brief: Inhibikase Therapeutics Announces Dosing Of First Patient In Its Phase 2A '201' Clinical Trial Of Ikt-148009 To Treat Parkinson's Disease
23/08/2022 13:13
Aug 23 (Reuters) - Inhibikase Therapeutics Inc IKT.O :
* INHIBIKASE THERAPEUTICS ANNOUNCES DOSING OF FIRST PATIENT
IN ITS
PHASE 2A '201' CLINICAL TRIAL OF IKT-148009 TO TREAT PARKINSON'S
DISEASE
Source text for Eikon: ID:nPn9jb4Z1a
Further company coverage: IKT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inhibikase Therapeutics
See all newsBrief: Inhibikase Therapeutics Appoints Scott Wasserman To Board Of Directors
Inhibikase Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Inhibikase Q2 net loss widens on higher R&D, SG&A costs
Inhibikase Therapeutics, Inc. expected to post a loss of 11 cents a share - Earnings Preview
Brief: Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share